Abstract Number: 2221 • 2016 ACR/ARHP Annual Meeting
Recognition of Secondary Fibromyalgia Using an Index of 3 Components of the Multi-Dimensional Health Assessment Questionnaire: 90% Agreement with ACR Criteria for Fibromyalgia
Background/Purpose: Secondary fibromyalgia (FM) is seen 15-20% of patients with rheumatoid arthritis (RA) (1), systemic lupus erythematosus (SLE) (2), osteoarthritis (OA), and other rheumatic diseases.…Abstract Number: 2222 • 2016 ACR/ARHP Annual Meeting
Tai Chi Is More Effective Than Aerobic Exercise in Treating Fibromyalgia: A Randomized Controlled Trial
Background/Purpose: Fibromyalgia is a complex disorder with strong psychological and pain components and is best managed with multidisciplinary therapies. Previous studies have suggested that Tai…Abstract Number: 2223 • 2016 ACR/ARHP Annual Meeting
Can Fibromyalgia be Empirically Defined By the Number of Pain Locations Plus Symptoms?
Background/Purpose: Both the revised 2010 FM criteria (Wolfe et al.) and the 2013 FM criteria (Bennett et al.), rely on counting the number of pain…Abstract Number: 2224 • 2016 ACR/ARHP Annual Meeting
Influence of Caffeine on Opioid Analgesics in Fibromyalgia
Background/Purpose: Caffeine’s action as an NSAID adjuvant are well understood, yet little clinical research has explored its effects on opioid analgesia. We present data from…Abstract Number: 2225 • 2016 ACR/ARHP Annual Meeting
Treatment Outcomes of Newly and Formerly Diagnosed Patients with Fibromyalgia after Fibromyalgia Treatment Program
Background/Purpose: We compared treatment outcomes between newly diagnosed versus formerly diagnosed patients seen in the brief interdisciplinary fibromyalgia treatment program (FTP). The FTP includes diagnostic…Abstract Number: 2226 • 2016 ACR/ARHP Annual Meeting
Independent and Combined Association of Overall Physical Fitness and Subjective Well-Being Components with Fatigue in Fibromyalgia
Background/Purpose: The highest prevalence of severe fatigue in rheumatic diseases is observed in FM1. Physical fitness and subjective well-being have been suggested as resilience resources…Abstract Number: 2227 • 2016 ACR/ARHP Annual Meeting
Sustained Remission and Relapse Rate after Non-Conventional DMARD Withdrawal in Patients with Rheumatoid Arthritis
Background/Purpose: The treatment of rheumatoid arthritis (RA) has evolved continuously. The introduction of non-conventional DMARDs, which include biologic and targeted synthetic DMARDs (tsDMARDs), has been…Abstract Number: 2228 • 2016 ACR/ARHP Annual Meeting
Real-World Cost of Treating Inadequate Responders to Anti-Tumor Necrosis Factor Therapy
Background/Purpose: RA patients (pts) receiving anti-TNF therapy may have an inadequate response (IR) to 1st-line treatment. Among pts for whom treatment fails, little is known…Abstract Number: 2229 • 2016 ACR/ARHP Annual Meeting
Economic Burden of Rheumatoid Arthritis Is Higher for ACPA-Positive Patients
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) have emerged as promising serological biomarkers of rapidly progressing RA and are associated with more severe disease and joint damage.…Abstract Number: 2230 • 2016 ACR/ARHP Annual Meeting
Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients
Background/Purpose: The goal of this study was to validate a claims-based statistical model to predict disease activity measured by the 28-joint count Disease Activity Score…Abstract Number: 2231 • 2016 ACR/ARHP Annual Meeting
Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher healthcare utilization (HCU) and costs than patients without RA1. Evidence is mixed as to the impact of…Abstract Number: 2232 • 2016 ACR/ARHP Annual Meeting
Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
Title: Above-Label Dosing with Biologics in Treatment-Naïve and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2…Abstract Number: 2233 • 2016 ACR/ARHP Annual Meeting
Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease requiring continuous therapy to reach low disease activity targets and to delay its long-term health effects.…Abstract Number: 2234 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2 Affiliations: 1Hospital for Special Surgery, New York, NY, US; 2Novartis Pharmaceuticals Corporation, East Hanover,…Abstract Number: 2235 • 2016 ACR/ARHP Annual Meeting
Utilization of Ambulatory Physician Encounters, Emergency Room Visits and Hospitalizations By RA Patients: A 13 Year Population Health Study
Background/Purpose: To determine total and subspecialty physician encounters, emergency room (ER) visits and hospitalizations in an incident cohort of rheumatoid arthritis (RA) cases and matched…
ACR Meeting Abstracts